• FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC pharmaceutical-technology
    February 06, 2017
    The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Opdivo injection (nivolumab) for intravenous use in previously treated, locally advanced or metastatic urothelial carcinoma (mUC), a type of bladder cancer.
PharmaSources Customer Service